▲ +68.60% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Hookipa Pharma in the last 3 months. The average price target is $21.14, with a high forecast of $28.00 and a low forecast of $16.00. The average price target represents a 68.60% upside from the last price of $12.54.
The current consensus among 7 contributing investment analysts is to buy stock in Hookipa Pharma.
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.